Rethinking the Inflammatory Balance in Psoriasis and Atherosclerosis

August 2023 | Volume 22 | Issue 8 | 832 | Copyright © August 2023


Published online July 31, 2023

Sophie Guenin MSca, Abrahem Kazemi MDa, Abigail Cline MD PhDa, Steven R. Feldman MD PhDb,c,d, Bijan Safai MD DSca

aDepartment of Dermatology, New York Medical College/Metropolitan Hospital Center, New York, NY 
bCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC
cDepartment of Pathology, Wake Forest School of Medicine, Winston-Salem, NC
dDepartment of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC



only immune-modulating biologic that reduces cardiovascular events independent of lipid reduction. Thus, instead of a general reduction in inflammation, we should strive to identify how inflammation should be modulated to reduce cardiovascular risk. A deeper understanding of the clinical implications of cytokine balance in psoriasis and cardiovascular disease is critical to target and reduce potential morbidity and mortality in these patients.

DISCLOSURES

Steven R. Feldman has received research, speaking, and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, Eurofins, Informa, UpToDate and the National Psoriasis Foundation. He is the founder and part owner of Causa Research and holds stock in Sensal Health. Authors Guenin, Kazemi, Cline, and Safai have no conflicts of interest to declare.

REFERENCES

  1. González-Cantero A, Ortega-Quijano D, Álvarez-Díaz N, et al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: A systematic review and meta-analysis of randomized placebo-controlled trials. J Invest Dermatol. 2021;141(10):2402-2411.
  2. Bissonnette R, Harel F, Krueger JG, et al. TNF-α antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol. 2017;137(8):1638-1645.
  3. Wu JJ, Sundaram M, Cloutier M, et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study. J Am Acad Dermatol. 2018;79(1):60-68.
  4. Hadebe N, Cour M, Lecour S. The SAFE pathway for cardioprotection: is this a promising target? Basic Res Cardiol. 2018;113(2):9.
  5. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-3140.
  6. Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140(9):1784-1793.
  7. Smith E, Prasad KM, Butcher M, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2010;121(15):1746-1755.
  8. Circulation. 2010;121(15):1746-1755.

AUTHOR CORRESPONDENCE

Sophie Guenin MSc Sophiehelene.guenin@gmail.com
Close Menu